Innovative Treatment-Convalescent Plasma Therapy for COVID-19

In News

Sree Chitra Tirunal Institute for Medical Science and
Technology (SCTIMST) developed an innovative treatment for the COVID-19
disease called Convalescent Plasma Therapy.

In-Detail

SCTIMST,
an institute of national importance has taken a progressive step
for the treatment of COVID-19 patients.

The Convalescent Plasma Therapy aims to use the
immune power of a recovered COVID-19 person for treatingan infected person.

The Indian Council for Medical Research (ICMR)
has given the approval for carrying out the novel treatment.

SCTIMST has applied for permissions to the Drug
Controller General of India (DCGI) for relaxation of the norms for blood
donation.

This plasma therapy is a passive immunization,
where the protection given is temporary.

The effectiveness of the treatment lasts till
the antibodies injected remain in the bloodstream.

This is an experimental therapy restricted for
severely affected patients only and conducted as a clinical trial.

COVID clinics of five medical college hospitals
are partnering with SCTIMST.

Mode of Treatment

First, the potential donor has to undergo a
blood test. The test must be negative for COVID-19 and the donor had to be
declared cured. Then the potential donor has to be asymptomatic for 28 days.

Then the blood is collected from the donor and
serum is separated.

The serum is screened for
virus-neutralisingantibodies i.e. convalescent serum.

Convalescent serum, rich in antibodies for the
pathogen is administrated to the diseased patient.

The antibody will stay for at least two to four
days on the recipient. During this period, the patient will recover.

The immune system mounts robust combat on the
virus with the help of the antibody.

Research reports from the USA and China show
that the beneficial effect of recovery from plasma transfusion is gained in the
first three to four days and the effect is not visible later.

How Safe Is The
Treatment?

With modern blood banking techniques, it is not
difficult to match the blood type donor and the recipient. The risks of
transferring known infectious agents are low.

Before donating the blood, the donor will be
examined and tested for mandatory factors such as hepatitis, HIV, malaria, and
so on to ensure that different pathogens are not transmitted to the recipient.

Challenges

This therapy is not simple, due to the
difficulty in acquiring the significant amounts of plasma from the survivors.

Most of the victims of COVID-19 are aged
patients and suffering from other medical conditions such as hypertension and
diabetes. So not all the recovered patients can donate the blood.

Institute of National Importance

The premier public higher education institutions
in India are awarded as Institute of National Importance (INI) by an Act of
Parliament. These institutions are pivotal players in developing highly skilled
personnel within the specified region.

INIs receive special recognition and funding
from the Government of India.